New drug combo for Ph+ ALL without transplant
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a combination of three drugs—olverembatinib, a bispecific T-cell engager, and chidamide—for adults newly diagnosed with Ph+ ALL who cannot have a stem cell transplant. The goal is to see if this treatment works well without needing intensive chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been newly diagnosed with a specific type of leukemia called Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
- You are 18 years old or older.
- You are unable to receive a stem cell transplant (allo-HSCT).
- You have good kidney and liver function (blood tests will check this).
- You have not had any prior chemotherapy or CAR-T therapy for ALL.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two medicines together: olverembatinib (a pill) and blinatumomab (given by infusion). It is for people who are newly diagnosed with Ph+ ALL and have not had chemotherapy yet. The goal is to see if this combination works well and is safe.
This trial tests a combination of targeted drugs (ABL/JAK inhibitors) with chemotherapy and venetoclax for people with a type of leukemia called Ph-like ALL. It aims to see if this treatment is safe and effective.
This trial tests a combination of two targeted drugs (blinatumomab and asciminib) for people with a specific type of leukemia (Ph+ ALL). The goal is to see if the combination works better than either drug alone in controlling the leukemia.
This trial tests a treatment plan for adults with a type of blood cancer called ALL that is newly diagnosed and not Philadelphia chromosome-positive. The goal is to see how well the treatment works and if it is safe for patients who have not had prior therapy.
This trial tests a combination of two targeted drugs given before a stem cell transplant for people with a specific type of acute lymphoblastic leukemia (Ph+ ALL) that did not fully respond to initial treatment. The goal is to make the leukemia undetectable before transplant, which may improve outcomes.
This trial tests a combination of chemotherapy and targeted immunotherapy for people with a specific type of leukemia (Ph+ ALL) that has not been treated before. The goal is to see if this approach can help control the disease better.
Hear when a new Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.